GlaxoSmithKline: Cough trials

The registry lists 14 Cough studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 10Phase 2 2Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China ExtensionRecruitingNCT07650084Phase 3
• A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of AgeCompletedNCT06222892Phase 1Results posted
• Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and CamlipixantCompletedNCT05959447Phase 1Results posted
• Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of CamlipixantCompletedNCT05899829Phase 1Results posted
• A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic CoughTerminatedNCT03372603Phase 1/2Results posted
• GSK2339345 Hypertussive Challenge StudyCompletedNCT01899768Phase 2Results posted
• A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation PrototypesWithdrawnNCT07684586Phase 1
• A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy ParticipantsCompletedNCT06497517Phase 1
• A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughActive, not recruitingNCT05600777Phase 3
• A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughCompletedNCT05599191Phase 3
• Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference FormulationCompletedNCT05570539Phase 1
• BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food EffectCompletedNCT03638180Phase 1
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.CompletedNCT01587716Phase 1
• The Safety, Tolerability, PK and PD of GSK2339345 in Healthy SubjectsCompletedNCT01494636Phase 1